预约演示
更新于：2026-02-26
Yttrium [90Y] chloride
钇90
更新于：2026-02-26
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2003-03-24), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式Y |
InChIKeyVWQVUPCCIRVNHF-OUBTZVSYSA-N |
CAS号10098-91-6 |
关联
19
项与 钇90 相关的临床试验NCT07334483
A Randomized, Active-Controlled, Open-Label Study of Yttrium [90Y] Microsphere Injection in Combination With Camrelizumab and/or Apatinib and Yttrium [90Y] Microsphere Injection Alone Versus cTACE in the Treatment of HCC
NCT06555133
A Phase II Pilot Study of yttriuM-90 in Combination With capEcitabine and aTezolizumab for oligomEtastatic cOlorectal Cancer With unResectable lIver MeTastasEs (METEORITE)
ChiCTR2500109289
Observation on the efficacy and safety of yttrium-90 microspheres injection combined with systemic therapy compared to transcatheter arterial chemoembolization (TACE) combined with systemic therapy in the downstaging treatment of hepatocellular carcinoma (HCC) beyond Hangzhou criteria
100 项与 钇90 相关的临床结果
登录后查看更多信息
100 项与 钇90 相关的转化医学
登录后查看更多信息
100 项与 钇90 相关的专利（医药）
登录后查看更多信息
2,626
项与 钇90 相关的文献（医药）2026-02-28Annals of hepato-biliary-pancreatic surgery
Liver hypertrophy post-Yttrium-90 versus portal vein embolization: A systematic review and meta-analysis
Article
作者: Christensen, Leslie ; Zafar, Syed Nabeel ; Ahmed, Kaleem Sohail ; Mahmud, Omar ; Virani, Sehar Salim ; Khan, Mustafa Ali ; Saqib, Sheza
Backgrounds/Aims:
Portal vein embolization (PVE) and Yttrium-90 (Y-90) radioembolization are used to induce liver hypertrophy, increasing future liver remnant volume and reducing the risk of post-resection liver failure. This systematic review compares the effectiveness of PVE and Y-90 radioembolization in promoting liver hypertrophy in patients undergoing liver resection.
Methods:
A systematic review was conducted in accordance with PRISMA guidelines. PubMed, Embase, Cochrane, and Web of Science were searched for studies published between January 2000 and August 2023. Studies comparing PVE and Y-90 radioembolization with respect to liver hypertrophy were included. Risk of bias was assessed using the Newcastle-Ottawa Scale. Pooled mean differences were calculated using an inverse-variance random-effects model.
Results:
Of 1,965 studies identified, three retrospective cohort studies met inclusion criteria, comprising 125 patients. Among these, 67.3% underwent PVE and 32.7% received Y-90 radioembolization. Hepatocellular carcinoma was the most common diagnosis (55.9%), followed by metastatic disease (32.3%) and cholangiocarcinoma (11.8%). PVE was more commonly used as a preoperative strategy for liver resection, while Y-90 radioembolization was primarily employed for palliative intent. One study reported greater hypertrophy with Y-90 compared to PVE (63% vs. 36%); however, hypertrophy was assessed over a longer interval (150 vs. 30 days). In pooled analysis, PVE was associated with significantly greater hypertrophy (mean difference 23.75%; 95% CI 12.02-35.48; p < 0.0001; I2 = 48%).
Conclusions:
Evidence directly comparing PVE and Y-90 radioembolization for liver hypertrophy remains limited. While pooled results favor PVE, procedure selection should be individualized based on clinical context.
2026-02-01ANNALS OF SURGICAL ONCOLOGY
Robotic Anatomic Right Hepatectomy for Recurrent Liver Tumor After Y-90 Radioembolization: Technique of Inflow Pedicle-Handling and IVC-Tumor Dissection
Article
作者: Sucandy, Iswanto ; Kumar, Shivanshu ; Ross, Sharona
BACKGROUND:
Major hepatectomy for patients after ytrium-90 (Y-90) treatment is technically difficult due to both intra- and extrahepatic fibroinflammatory changes induced by the radiembolization.1-5 Technical challenges at liver mobilization, inflow pedicle dissection and division, inferior vena cava (IVC) dissection, and parenchymal transection often discourage liver surgeons to use a minimally invasive approach in this circumstance. Although the robotic approach is considered best for technically difficult resections with potential vascular resection, detailed description of this operation in modern literature is limited. This report describes our standardized approach and the technical feasibility of robotic right hepatectomy after Y-90 radioembolization for recurrent colorectal liver metastasis with significant IVC contact.
METHODS:
A 63 year-old man with stage IV colon cancer presented with a recurrent 3.9 cm dorsal segment 7 hepatic lesion abutting the lateral wall of the IVC. He had previously undergone primary colonic resection using an open method, systemic chemotherapy treatment, and radioembolization 9 years earlier. Preoperative imaging with computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scan confirmed an isolated hypermetabolic mass consistent with metastatic tumor. Robotic formal right hepatectomy was undertaken under intermittent Pringle maneuvers as necessary. Due to dense fibrosis around the right perihilar region from the radioembolization preventing safe individual inflow vascular dissection, the intrahepatic Glissonean approach was used to transect the right anterior and posterior pedicle individually after initial parenchymal transection. Significant hypertrophy of the left hepatic lobe and atrophy of the right hepatic lobe after radioembolization also led to a positional rotation of the hilar region, which added further complexity to the hilar dissection. Once the liver was open-booked, IVC-tumor dissection was performed using the dual-bipolar Maryland technique under a low central venous pressure condition (<5 mmHg).
RESULTS:
The procedure was completed uneventfully with minimal blood loss. The postoperative recovery was uncomplicated, leading to a hospital discharge on postoperative day 4. The final pathology report confirmed a metastatic adenocarcinoma with negative resection margins. At the 1-year follow-up assessment, the patient remained disease-free.
DISCUSSION:
Robotic major hepatectomy after Y-90 is a particularly difficult operation technically due to several factors. Fibrotic changes in the hepatic hilum due to postprocedural and radiation-induced inflammation often lead to challenging dissection around the hepatic artery and portal vein while gaining inflow vascular control. The atrophy-hypertrophy changes of the liver lobes also lead to a rotation/anatomic shift of the porta hepatis, making extrahepatic isolation of the hepatic artery and portal vein more challenging. The fibroinflammatory reaction after Y-90 is associated with increased adhesions to the diaphragm and paracaval region during right hepatic lobe mobilization. This is more clinically relevant in cases of large tumors near or in contact with the IVC, as in the current case. Separation of the tumor off the IVC wall may require venorrhaphy and advanced suturing skills to avoid major hemorrhage. Inflamed and fibrotic changes within the liver parenchyma also increase the technical challenge during deep hepatic transection, which often are associated with more bleeding from highly fragile intrahepatic capillaries when the liver is transected. Finally, the dissection and final transection of the right hepatic vein off the IVC is often technically demanding due to the fibrosis that occurs around the hepatocaval confluence making smooth application of linear vascular stapler somewhat technically challenging.
CONCLUSION:
Despite of the technical challenges related to radioembolization, robotic major hepatectomy with paracaval tumor dissection obtaining R-0 margins is safe and feasible. Previous Y-90 therapy did not preclude a successful application of minimally invasive robotic resection with excellent clinical and oncologic outcomes.
2026-02-01NUCLEAR MEDICINE COMMUNICATIONS
Clinical impact of Yttrium-90 resin microsphere radioembolization-induced hepatic adverse events and associations with predictive dosimetry
Article
作者: Tong, Aaron Kian Ti ; Huang, Hian Liang ; Chen, Kaina ; Loke, Kelvin Siu Hoong ; Fong, Joanna Rui En ; Goh, Charles Xian Yang
Objective:
Radioembolization-induced liver disease (REILD) is a potentially life-threatening complication that can develop after yttrium-90 (Y-90) radioembolization. Our study determined to find associations between liver toxicity and Y-90 dosimetry.
Methods:
We analyzed cases of REILD and isolated hyperbilirubinemia that developed after Y-90 resin microsphere radioembolization for hepatocellular carcinoma with a focus on dosimetric parameters.
Results:
Out of a cohort of 413 patients, 12 patients developed REILD, and 17 patients had grade 3 isolated hyperbilirubinemia. All patients in the REILD group were Barcelona-Clinic Liver Cancer (BCLC) stage C, with portal vein thrombosis (PVT) on baseline imaging, and albumin–bilirubin (ALBI) score of 2. More cases of REILD had bilobar radioembolization compared with unilobar treatment. The median absorbed dose to nontumorous liver was 33.0 and 31.8 Gy for REILD and isolated hyperbilirubinemia, respectively. The median overall survival (mOS) for the REILD group was 5.1 months [interquartile range (IQR): 3.4–8.6 months], while mOS for the isolated hyperbilirubinemia group was 4.3 months (IQR: 2.9–5.3 months). Comparing patients with BCLC stage C in the larger database, those who developed REILD had poorer overall survival outcomes.
Conclusion:
Our study observed severe liver toxicity at absorbed doses below the recommended dose thresholds to nontumorous liver. ALBI scores greater than or equal to 2 predicted for postprocedural liver toxicities. Further prospective research is suggested to ascertain a safe absorbed dose threshold, incorporating ALBI, PVT status, and bilobar involvement. Caution is warranted when performing bilobar Y-90 radioembolization in ALBI greater than or equal to 2 patients, even at standard doses.
100 项与 钇90 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 诊断试剂 | 欧盟 | 2003-03-24 | |
| 诊断试剂 | 冰岛 | 2003-03-24 | |
| 诊断试剂 | 列支敦士登 | 2003-03-24 | |
| 诊断试剂 | 挪威 | 2003-03-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肝细胞癌 | 临床3期 | 中国 | 2021-09-13 | |
| 肝细胞癌 | 临床3期 | 中国 | 2021-09-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 63 | (SIRT with Y-90 resin microspheres) | 願窪糧襯夢襯積構廠衊(齋顧餘糧艱鹹蓋獵夢願) = developed in 8 (12.7%) patients and no serious AE was reported 鏇遞壓範艱醖鑰窪廠憲 (遞構鏇鏇繭壓獵鬱範齋 ) 更多 | 积极 | 2024-12-07 | ||
N/A | 63 | (SIRT with Y-90 resin microspheres) | 構艱餘範鏇範築鏇網遞(壓廠膚選廠醖顧膚積鏇) = developed in 8 (12.7%) patients and no serious AE was reported 餘願選壓觸艱鹹願築齋 (淵蓋網鹹窪積膚醖簾獵 ) 更多 | 积极 | 2024-12-07 | ||
N/A | - | 39 | (Hepatic transarterial radioembolization with yttrium-90 (TARE)) | 憲艱願醖醖襯衊鹽艱鹹(憲繭製艱願蓋繭壓醖鏇) = 餘糧構糧繭製選憲鹽蓋 壓鹽衊範選繭鏇壓糧憲 (網獵艱餘觸襯糧遞衊齋 ) 更多 | 积极 | 2024-09-27 | |
N/A | - | Yttrium-90 radioembolization (Y90 radioembolization) | 餘鑰醖艱夢餘餘範壓簾(餘構鏇選鹹選蓋築衊膚) = 積顧鏇襯糧遞選襯獵襯 製觸構艱獵觸餘積鏇膚 (艱齋襯鹽觸鬱憲構範積 ) | - | 2024-05-20 | ||
N/A | - | (90Y-glass radioembolization) | 膚壓築製製鏇鑰積網餘(願衊構鬱選夢製窪憲遞) = 醖蓋簾顧膚鬱鬱觸構鏇 範獵壓衊齋窪願構憲觸 (壓觸鹹餘鬱繭簾窪艱鹽 ) | - | 2022-08-08 | ||
N/A | 35 | (Patients with metastatic liver disease) | 鬱鹹鹽鏇齋鬱網顧鹹繭(簾艱鬱鏇範繭衊膚鹹淵) = 鑰窪襯憲廠襯衊製簾築 選鬱積遞網觸糧淵衊範 (鏇遞鹽膚積鹹鏇壓選淵, 4.9 (IQR 3.9 ~ 7.1)) 更多 | 积极 | 2021-05-18 | ||
N/A | 不能切除的乳腺癌 CA15-3 level | Albumin-Bilirubin (ALBI) | Model for end-stage liver disease (MELD) score | 32 | Yttrium-90 Glass Microsphere (Yttrium-90 (Y90) microspheres) | 鑰觸壓顧憲鹽製鏇積衊(繭廠夢構憲襯鑰膚觸願) = The 30-day mortality was 3.1%; 1 patient died from radioembolization-induced liver disease 衊繭廠網膚鏇鹽淵餘艱 (願艱醖夢鑰繭積醖獵壓 ) 更多 | 积极 | 2020-11-01 | |
N/A | 47 | Y-90 radioembolization | 襯鏇蓋膚鬱選艱餘鹹淵(獵網鏇壓觸鹽齋淵網製) = grade 3 abdominal pain (6%) 夢廠憲範壓選構範窪製 (糧襯顧鑰艱艱夢膚蓋衊 ) 更多 | 积极 | 2018-06-01 | ||
临床1期 | 20 | 鏇網鑰糧夢廠醖遞鬱構(願鹹製餘衊壓廠壓鏇選) = 選鹽簾夢糧網顧繭鑰獵 壓鏇積餘製積衊憲醖鏇 (構淵鏇網築願衊夢壓艱 ) | - | 2014-08-01 | |||
N/A | 56 | (Y90 radioembolization) | 夢鹽觸鬱獵襯膚範鑰夢(願獵願齋壓蓋齋製衊選) = 獵範網遞製憲膚鑰構顧 選衊簾鏇築製淵範遞遞 (夢醖齋繭製膚積繭艱鑰 ) 更多 | 积极 | 2014-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用